RxDoctor Payments Data

Elsa Correa-Deleonardo, NP

Psychiatric/Mental Health · Reisterstown, MDNPI 1396222907

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.5% of the total across 365 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$9,742in general payments, 2019–2025

Across 365 payments — averaging $26.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Otsuka America Pharmaceutical, Inc.$945
  • AbbVie$907
  • plus $3K from 11 others

What the payments were for

  • Food & beverage$9,68999%
  • Education$541%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,742 in reported general payments places this provider in the 95th percentile of 1,461 psychiatric/mental health providers in Maryland.

See all psychiatric/mental health providers in Maryland

Medicare billing

Part B allowed, 2024
$44,431
Medicare patients
39
Services billed
415

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Atomoxetine Hcl11$1,387
Duloxetine Hcl36$1,371
Oxcarbazepine21$1,286
Gabapentin62$750
Perphenazine11$591
Clonazepam74$555
Memantine Hcl ErMemantine Hcl14$547
Bupropion XlBupropion Hcl31$420
Quetiapine Fumarate29$404
Fluvoxamine Maleate20$380
Topiramate37$341
Risperidone23$307
Trazodone Hcl44$303
Buspirone Hcl30$231
Venlafaxine Hcl12$215

Paid to pharmacies, not to this prescriber.

Other psychiatric/mental health in Reisterstown

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →